Core Viewpoint - The company, Zhi Sheng Bio (300871.SZ), has announced a profit forecast for the year 2025, expecting a net profit attributable to shareholders of between 235 million yuan and 271 million yuan, marking a turnaround from losses to profits [1] Financial Performance - The forecasted net profit after deducting non-recurring gains and losses is estimated to be between 213 million yuan and 249 million yuan [1] - The company is actively expanding both domestic and international markets, leading to revenue growth in both areas [1]

Core Viewpoint - The company, Ruisong Bio, expects a significant turnaround in its financial performance for 2025, projecting a net profit attributable to shareholders of between 235 million and 271 million yuan, compared to a loss of 20.16 million yuan in the same period last year [1] Group 1: Financial Performance - The projected net profit for 2025 represents a substantial increase compared to the previous year's loss, indicating a strong recovery [1] - The company attributes the expected profit growth to increased operating revenue driven by both domestic and international market expansion [1] Group 2: Operational Factors - Key factors contributing to the profit increase include technological innovation, improved utilization rates of both formulations and active pharmaceutical ingredients, and rising prices of raw materials [1]

Core Viewpoint - The report from Kaiyuan Securities highlights that BioShares is a leading player in China's animal health sector, with a diverse range of over a hundred vaccines covering pigs, poultry, ruminants, and pets. The company is expected to see significant growth driven by its new vaccines, particularly the African swine fever vaccine, which is nearing market launch [1] Financial Projections - The company maintains its profit forecast for 2025 while raising the profit estimates for 2026 and 2027. The projected net profits for 2025, 2026, and 2027 are 188 million, 712 million, and 1.211 billion yuan respectively, with earnings per share (EPS) of 0.17, 0.64, and 1.09 yuan [1] - The previous profit forecasts for 2026 and 2027 were 352 million and 508 million yuan respectively [1] Valuation Metrics - The current price-to-earnings (PE) ratios for the company are projected to be 98.5, 25.9, and 15.3 for the years 2025, 2026, and 2027 respectively [1] Investment Rating - The company is expected to maintain strong growth momentum with the imminent global launch of its African swine fever vaccine, leading to a "buy" rating [1]

Core Viewpoint - The significant upward revision of profit forecasts for Shenghua Co. (600201.SH) by Kaiyuan Securities reflects a strong confidence in the company's growth prospects, particularly driven by the development of the African swine fever vaccine [1][6]. Group 1: Profit Forecast Adjustments - In late October 2025, Kaiyuan Securities provided a cautious profit forecast for Shenghua Co. for 2025-2027, estimating net profits of 1.88 billion, 3.52 billion, and 5.08 billion respectively [2]. - By January 8, 2026, the profit forecast for 2026 was dramatically increased to 7.12 billion, nearly doubling the previous estimate, while the 2027 forecast rose by over 138% to 12.11 billion [2]. Group 2: Key Drivers of Growth - The major adjustment in profit forecasts is primarily attributed to the unexpected progress in the research and development of the African swine fever subunit vaccine, with Shenghua Co. being the first and only company in China approved for clinical trials [3]. - The vaccine is expected to create an incremental market size of approximately 84 billion in China, positioning Shenghua Co. as a significant beneficiary due to its first-mover advantage [3]. Group 3: Traditional Business Performance - Besides the potential of the African swine fever vaccine, Shenghua Co.'s traditional business is also showing steady growth, with a 50% year-on-year increase in sales of foot-and-mouth disease vaccines in the first three quarters of 2025 [4]. - Other vaccine products, including those for ruminants, poultry, and pets, are also experiencing strong growth, supported by a robust investment in R&D, which accounted for 13.51% of revenue in the first half of 2025 [4].

Group 1 - South Africa is experiencing the most severe foot-and-mouth disease outbreak in its history, with rapid virus transmission and strong infectivity, posing an unprecedented disaster for the livestock industry [1] - The outbreak began in April 2025 in KwaZulu-Natal province and has spread to other key agricultural areas, prompting the South African Department of Agriculture to procure vaccines for emergency vaccination of 930,000 animals [1] - The outbreak highlights the importance of global animal disease prevention and presents overseas market expansion opportunities for domestic animal health companies with technological advantages [1] Group 2 - The animal health industry has a tightly linked upstream and downstream, with upstream raw material drug companies providing essential support for vaccine production, while downstream demand from farming recovery and overseas epidemic prevention needs drive industry growth [2] - Companies like Reap Bio focus on veterinary biological products, including foot-and-mouth disease vaccines, covering multiple sectors such as pigs, poultry, and pets [3] - Bio Company is a leading domestic animal health enterprise with designated production qualifications for strong immunity foot-and-mouth disease vaccines, consistently ranking first in the industry for vaccine batch approvals [4]

从资金流向上来看，当日动物保健板块主力资金净流入1429.81万元，游资资金净流出3379.23万元，散户 资金净流入1949.42万元。动物保健板块个股资金流向见下表： 证券之星消息，1月6日动物保健板块较上一交易日上涨0.83%，*ST绿康领涨。当日上证指数报收于 4083.67，上涨1.5%。深证成指报收于14022.55，上涨1.4%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 002868 | *ST绿康 | 37.17 | 5.00% | 7510.0 | 2772.39万 | | 300871 | 回盛生物 | 21.92 | 3.15% | 9.40万 | 2.03亿 | | 920970 | 大禹生物 | 7.95 | 2.71% | 1.84万 | 1449.96万 | | 920729 | 永顺生物 | 8.90 | 2.06% | 1.12万 | 992.55万 | | 920275 | 驱动力 | 9.05 | 1.57% | 1.01 ...

Core Viewpoint - The animal health sector experienced a significant increase of 3.8% on January 5, with Haili Biological leading the gains, while the overall market indices also showed positive performance [1] Group 1: Market Performance - The Shanghai Composite Index closed at 4023.42, up by 1.38% [1] - The Shenzhen Component Index closed at 13828.63, up by 2.24% [1] Group 2: Individual Stock Performance - Haili Biological (603718) closed at 6.58, with a rise of 7.87% and a trading volume of 461,200 shares, amounting to a transaction value of 302 million yuan [1] - Biological Shares (600201) closed at 16.06, increasing by 6.57% with a trading volume of 553,300 shares, totaling 88.5 million yuan [1] - ST Green Health (002868) closed at 35.40, up by 5.01% with a trading volume of 14,600 shares, amounting to 5.124 million yuan [1] - Shunlian Biological (688098) closed at 9.29, increasing by 4.62% with a trading volume of 65,000 shares, totaling 60.117 million yuan [1] - Ruipu Biological (300119) closed at 19.53, up by 4.05% with a trading volume of 78,500 shares, amounting to 151 million yuan [1] - KQ Biological (688526) closed at 15.68, increasing by 2.75% with a trading volume of 29,900 shares, totaling 46.631 million yuan [1] - Huisheng Biological (300871) closed at 21.25, up by 2.51% with a trading volume of 61,500 shares, amounting to 129 million yuan [1] - Qudongli (920275) closed at 8.91, increasing by 2.30% with a trading volume of 10,300 shares, totaling 911,930 yuan [1] - Placo (603566) closed at 12.71, up by 2.25% with a trading volume of 36,700 shares, amounting to 46.3405 million yuan [1] - Jinhai Biological (002688) closed at 6.03, increasing by 1.34% with a trading volume of 105,100 shares, totaling 63.2745 million yuan [1] Group 3: Capital Flow Analysis - The animal health sector saw a net inflow of 77.0149 million yuan from main funds, while retail funds experienced a net outflow of 33.0955 million yuan [1] - The main funds' net inflow for Haili Biological was -54.2922 million yuan, with a net outflow from retail funds of -35.0631 million yuan [2] - Ruipu Biological had a net inflow of 15.0755 million yuan from main funds, while retail funds saw a net inflow of 555.73 thousand yuan [2] - Biological Shares had a net inflow of 1.5843 million yuan from main funds, with a net outflow from retail funds of -1529.42 thousand yuan [2]

Investment Rating - The industry investment rating is "Positive" and is maintained [5] Core Viewpoints - The pig farming sector is expected to benefit from recent policies and market dynamics that promote capacity reduction, leading to a potential price turning point in Q2 2026, with long-term performance improvements anticipated for related stocks [3][43] - The structural growth trend in the post-cycle sector continues, with profits likely to gradually transmit downstream if the current round of pig capacity reduction proceeds smoothly, benefiting the animal health sector [3] - The planting chain shows a confirmed upward trend in grain prices, indicating favorable fundamentals for planting and seed industries, highlighting significant investment opportunities [3] - The pet food sector is experiencing growth and price increase logic, with continuous recognition of domestic brands and sustained growth of leading companies [3] Summary by Sections Pig Farming - The average price of live pigs as of December 31 was 12.76 yuan/kg, a week-on-week increase of 10.38%, while the average price of 15 kg piglets was 19.44 yuan/kg, up 2.21% week-on-week [12][51] - The supply side shows a widening price gap for fattened pigs, supporting price increases, while demand is boosted by consumption expectations during the New Year holiday [12][17] Poultry - The price of white feather broilers increased to 7.82 yuan/kg, up 6.39% week-on-week, and chick prices rose to 3.59 yuan/chick, up 1.7% week-on-week [17][51] - The supply of meat chickens has increased, leading to a more relaxed market supply, while demand has weakened due to some slaughterhouses reducing operations [17] Feed Sector - The prices of corn, wheat, and soybean meal have risen, with corn averaging 2351.57 yuan/ton, up 0.57% week-on-week, and soybean meal at 3172.29 yuan/ton, up 0.96% week-on-week [27][51] - Increased selling enthusiasm among farmers is noted, although the pace of supply remains slow [27] Major Agricultural Products - The domestic natural rubber futures price was 15605 yuan/ton as of December 31, down 0.29% week-on-week, with inventory levels increasing [38][51] - The current down cycle for sugar prices continues, with no significant recovery expected [39]

Group 1 - The core stock price of Huisheng Biological (300871) closed at 20.73 yuan on December 31, 2025, reflecting an increase of 0.58% from the previous week's closing price of 20.61 yuan [1] - The highest intraday price for Huisheng Biological during the week was 21.01 yuan, while the lowest was 20.43 yuan [1] - The current total market capitalization of Huisheng Biological is 4.194 billion yuan, ranking 8th out of 11 in the animal health sector and 3819th out of 5181 in the A-share market [1] Group 2 - Huisheng Biological received the first phase of government subsidy amounting to 2.25 million yuan on December 26, 2025, which represents 11.16% of the latest audited net profit [1] - The total amount of the project subsidy is 10 million yuan, which will be disbursed in phases [1] - This subsidy is related to revenue and is associated with the company's regular business activities, and it has already been received [1]

Core Viewpoint - The animal health sector experienced a slight decline of 0.05% on December 31, with Xianfeng Holdings leading the drop. The Shanghai Composite Index rose by 0.09%, while the Shenzhen Component Index fell by 0.58 [1] Group 1: Market Performance - The closing price of Xianfeng Holdings was 3.73, down by 2.61%, with a trading volume of 182,700 shares and a transaction amount of 68.47 million [2] - The animal health sector's main stocks showed mixed performance, with *ST Lvkang rising by 2.46% to 33.71, while several others, including Xianfeng Holdings and Ruipu Bio, saw declines [1][2] - The total trading volume in the animal health sector was significant, with major stocks like Ruipu Bio and Xianfeng Holdings contributing to the overall market activity [2] Group 2: Capital Flow - The animal health sector saw a net outflow of 45.26 million from institutional investors, while retail investors contributed a net inflow of 39.94 million [2] - The capital flow data indicates that retail investors were more active in the market, with a notable net inflow compared to the outflow from institutional investors [2] - Specific stocks like Huisheng Bio and *ST Lvkang had varying levels of net inflow and outflow from different investor categories, reflecting diverse investor sentiment [3]